- Home
- RNTX vs USEG Comparison
RNTX vs USEG Comparison
Compare RNTX & USEG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RNTX
- USEG
- Stock Information
- Founded
- RNTX 2001
- USEG 1966
- Country
- RNTX United States
- USEG United States
- Employees
- RNTX N/A
- USEG N/A
- Industry
- RNTX Biotechnology: Pharmaceutical Preparations
- USEG Oil & Gas Production
- Sector
- RNTX Health Care
- USEG Energy
- Exchange
- RNTX Nasdaq
- USEG Nasdaq
- Market Cap
- RNTX 40.3M
- USEG 42.2M
- IPO Year
- RNTX N/A
- USEG N/A
- Fundamental
- Price
- RNTX $1.56
- USEG $1.77
- Analyst Decision
- RNTX
- USEG Strong Buy
- Analyst Count
- RNTX 0
- USEG 2
- Target Price
- RNTX N/A
- USEG $2.75
- AVG Volume (30 Days)
- RNTX 33.6K
- USEG 8.2M
- Earning Date
- RNTX 08-13-2025
- USEG 08-06-2025
- Dividend Yield
- RNTX N/A
- USEG N/A
- EPS Growth
- RNTX N/A
- USEG N/A
- EPS
- RNTX N/A
- USEG N/A
- Revenue
- RNTX N/A
- USEG $16,340,000.00
- Revenue This Year
- RNTX N/A
- USEG $23.82
- Revenue Next Year
- RNTX N/A
- USEG N/A
- P/E Ratio
- RNTX N/A
- USEG N/A
- Revenue Growth
- RNTX N/A
- USEG N/A
- 52 Week Low
- RNTX $1.35
- USEG $0.81
- 52 Week High
- RNTX $4.40
- USEG $6.40
- Technical
- Relative Strength Index (RSI)
- RNTX N/A
- USEG 57.29
- Support Level
- RNTX N/A
- USEG $1.65
- Resistance Level
- RNTX N/A
- USEG $2.43
- Average True Range (ATR)
- RNTX 0.00
- USEG 0.25
- MACD
- RNTX 0.00
- USEG 0.06
- Stochastic Oscillator
- RNTX 0.00
- USEG 35.78
About RNTX Rein Therapeutics Inc. Common Stock
Rein Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing therapies in orphan pulmonary and fibrosis indications, including two Phase 2-ready clinical assets. The company's product candidate includes LTI-03: a peptide for which company conducted a Phase 1b dose-ranging, placebo-controlled safety, tolerability, and pharmacodynamic biomarker activity trial in development for the treatment of Idiopathic Pulmonary Fibrosis; LTI-01: proenzyme that completed a Phase 2a dose-ranging, placebo-controlled trial and a Phase 1b safety, tolerability and proof of mechanism trial in loculated pleural effusion, or LPE, patients, an indication that has no approved drug treatment; and LTI-05 and others.
About USEG U.S. Energy Corp. (DE)
US Energy Corp is an independent energy company. It is focused on the acquisition and development of oil and natural gas-producing properties in the continental United States. It has business properties and operations in the Rockies region (Montana, Wyoming, and North Dakota), the Mid-Continent (Oklahoma, Kansas, and North and East Texas), and the West Texas, South Texas, and Gulf Coast regions. The company generates revenue from its interest in the sales of oil and natural gas production. The group operates in the exploration and production segment of the oil and gas industry, onshore in the United States.